Reverse DCF
What growth does the market imply for CONCORDBIO?
Working backwards from the current price to find the FCF growth assumption baked in.
aggressive
16.8% implied annual FCF growth
The market is pricing in above-average growth. Achievable for a high-quality business but leaves limited margin for error — any slowdown could hurt the price.
Current Price
₹1,362
Historical Growth
7.0%
FCF Yield
2.04%
Price / FCF
49.1x
Plain English
To justify today's price of ₹1361.70, CONCORDBIO.NS needs to grow its free cash flow at 16.8% per year for the next 10 years. That is 9.8% faster than its historical growth rate of 7.0%. This is optimistic but not impossible for a high-quality business. The stock leaves little room for error — any slowdown could hurt the price.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 7.0% | ₹630 | -53.8% |
| Half implied | 8.4% | ₹705 | -48.2% |
| GDP rate | 10.0% | ₹802 | -41.1% |
| Implied | 16.8% | ₹1,362 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 7.0% growth, the model values CONCORDBIO at ₹630, below today's ₹1,362.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.